20 results on '"Romano, Rosalia"'
Search Results
2. Robotic-assisted thymectomy for early-stage thymoma: a propensity-score matched analysis
- Author
-
Casiraghi, Monica, Galetta, Domenico, Borri, Alessandro, Tessitore, Adele, Romano, Rosalia, Brambilla, Daniela, Maisonneuve, Patrick, and Spaggiari, Lorenzo
- Published
- 2018
- Full Text
- View/download PDF
3. Surgical Treatment in Patient with Non–Small-Cell Lung Cancer with Fissure Involvement: Anatomical versus Nonanatomical Resection
- Author
-
Leuzzi, Giovanni, Cesario, Alfredo, Cafarotti, Stefano, Lococo, Filippo, Dall’Armi, Valentina, Novellis, Pierluigi, Romano, Rosalia, Siciliani, Alessandra, Meacci, Elisa, Granone, Pierluigi, and Margaritora, Stefano
- Published
- 2014
- Full Text
- View/download PDF
4. A new sign of the slipping rib syndrome?
- Author
-
Romano, Rosalia, primary, Gavezzoli, Diego, additional, Gallazzi, Maria Sole, additional, and Benvenuti, Mauro Roberto, additional
- Published
- 2021
- Full Text
- View/download PDF
5. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis
- Author
-
Milione, Massimo, primary, Maisonneuve, Patrick, additional, Grillo, Federica, additional, Mangogna, Alessandro, additional, Centonze, Giovanni, additional, Prinzi, Natalie, additional, Pusceddu, Sara, additional, Garzone, Giovanna, additional, Cattaneo, Laura, additional, Busico, Adele, additional, Bossi, Paola, additional, Spaggiari, Paola, additional, Pellegrinelli, Alessio, additional, Del Gobbo, Alessandro, additional, Ferrero, Stefano, additional, Kankava, Ketevani, additional, Pruneri, Giancarlo, additional, Rolli, Luigi, additional, Roca, Elisa, additional, Bercich, Luisa, additional, Tironi, Andrea, additional, Benvenuti, Mauro Roberto, additional, Gallazzi, Maria Sole, additional, Romano, Rosalia, additional, Berruti, Alfredo, additional, Pastorino, Ugo, additional, and Capella, Carlo, additional
- Published
- 2020
- Full Text
- View/download PDF
6. Two-step investigation of lung cancer detection by sniffer dogs
- Author
-
Mazzola, Silvia Michela, primary, Pirrone, Federica, additional, Sedda, Giulia, additional, Gasparri, Roberto, additional, Romano, Rosalia, additional, Spaggiari, Lorenzo, additional, and Mariangela, Albertini, additional
- Published
- 2020
- Full Text
- View/download PDF
7. Erratum to: Ten Years' Experience in Robotic-Assisted Thoracic Surgery for Early Stage Lung Cancer
- Author
-
Casiraghi, Monica, additional, Galetta, Domenico, additional, Borri, Alessandro, additional, Tessitore, Adele, additional, Romano, Rosalia, additional, Diotti, Cristina, additional, Brambilla, Daniela, additional, Maisonneuve, Patrick, additional, and Spaggiari, Lorenzo, additional
- Published
- 2019
- Full Text
- View/download PDF
8. Ten Years' Experience in Robotic-Assisted Thoracic Surgery for Early Stage Lung Cancer
- Author
-
Casiraghi, Monica, additional, Galetta, Domenico, additional, Borri, Alessandro, additional, Tessitore, Adele, additional, Romano, Rosalia, additional, Diotti, Cristina, additional, Brambilla, Daniela, additional, Maisonneuve, Patrick, additional, and Spaggiari, Lorenzo, additional
- Published
- 2018
- Full Text
- View/download PDF
9. Diagnostic biomarkers for lung cancer prevention
- Author
-
Gasparri, Roberto, primary, Romano, Rosalia, additional, Sedda, Giulia, additional, Borri, Alessandro, additional, Petrella, Francesco, additional, Galetta, Domenico, additional, Casiraghi, Monica, additional, and Spaggiari, Lorenzo, additional
- Published
- 2018
- Full Text
- View/download PDF
10. Endobronchial Ultrasound Transbronchial Needle Aspiration in Thoracic Diseases: Much More than Mediastinal Staging
- Author
-
Guarize, Juliana, primary, Casiraghi, Monica, additional, Donghi, Stefano, additional, Diotti, Cristina, additional, Vanoni, Nicolo, additional, Romano, Rosalia, additional, Casadio, Chiara, additional, Brambilla, Daniela, additional, Maisonneuve, Patrick, additional, Petrella, Francesco, additional, and Spaggiari, Lorenzo, additional
- Published
- 2018
- Full Text
- View/download PDF
11. Ten Years' Experience in Robotic-Assisted Thoracic Surgery for Early Stage Lung Cancer.
- Author
-
Casiraghi, Monica, Galetta, Domenico, Borri, Alessandro, Tessitore, Adele, Romano, Rosalia, Diotti, Cristina, Brambilla, Daniela, Maisonneuve, Patrick, and Spaggiari, Lorenzo
- Subjects
THORACIC surgery ,PNEUMONECTOMY ,NON-small-cell lung carcinoma ,LUNG cancer ,TUMOR classification ,LYMPHADENECTOMY - Abstract
Background This study analyzed the short- and long-term outcomes of robotic-assisted thoracic surgery (RATS) for early stage non-small cell lung cancer (NSCLC). Methods From November 2006 to December 2016, we performed 363 RATS procedures. This study retrospectively reviewed 339 patients who underwent RATS for clinical stages I (n = 318) or II (n = 21) NSCLC. Results Twenty-nine patients underwent segmentectomy, 307 lobectomy, and 3 pneumonectomy. Conversion occurred in 22 patients (6.5%): 15 (4.4%) due to technical issues, 4 (1.2%) for oncological reasons, and 3 (0.9%) for bleeding. The median number of N1 and N2 stations resected was 2 and 3, respectively, and the median number of N1 and N2 lymph nodes resected was 9 and 6, respectively. Median operative time was 192 minutes for lobectomy, 172 minutes for segmentectomy, and 275 minutes for pneumonectomy. Median length of hospital stay was 5 days (2–191). The most common postoperative complication was prolonged air leak (12.1%). Major complications occurred in eight patients (2.4%). The 30-day and 90-day operative mortality was 0% and 0.3%, respectively. Two and 5-year cancer-specific survival rate was 96.1% and 91.5%, respectively. Five-year survival rate was 96.2% for patients who underwent segmentectomy, and 89.1% for lobectomy. All three patients who underwent pneumonectomy were alive at 5 years with no disease. Conclusions Besides the well-known short-term outcomes showing very low morbidity and mortality rates, mediastinal lymph node dissection during RATS adequately assesses lymph node stations detecting occult lymph node metastasis and leading to excellent oncologic results. However, these results await longer follow-up studies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. Long-term results in patients with pathological complete response after induction radiochemotherapy followed by surgery for locally advanced non-small-cell lung cancer.
- Author
-
Granone, Pierluigi, Lococo, Filippo, Cesario, Alfredo, Margaritora, Stefano, Dell'Armi, Valentina, Mattei, F., Romano, Rosalia, Porziella, Venanzio, Granone, Pierluigi (ORCID:0000-0002-8826-3045), Lococo, Filippo Maria (ORCID:0000-0002-9383-5554), Cesario, Alfredo (ORCID:0000-0003-4687-0709), Margaritora, Stefano (ORCID:0000-0002-9796-760X), Porziella, Venanzio (ORCID:0000-0001-6000-3172), Granone, Pierluigi, Lococo, Filippo, Cesario, Alfredo, Margaritora, Stefano, Dell'Armi, Valentina, Mattei, F., Romano, Rosalia, Porziella, Venanzio, Granone, Pierluigi (ORCID:0000-0002-8826-3045), Lococo, Filippo Maria (ORCID:0000-0002-9383-5554), Cesario, Alfredo (ORCID:0000-0003-4687-0709), Margaritora, Stefano (ORCID:0000-0002-9796-760X), and Porziella, Venanzio (ORCID:0000-0001-6000-3172)
- Abstract
OBJECTIVES: The outcome of locally advanced non-small-cell lung cancer (NSCLC) patients with pathological complete response (pCR)-pT0N0 -after induction chemoradiotherapy (IT) followed by surgery has, to date, only rarely been investigated. The long-term results in this highly selected subset of patients were evaluated and reported here to identify any predictive factors associated with prognosis. METHODS: From January 1992 to December 2009, 195 consecutive locally advanced (T1-T4/N0-2/M0) NSCLC patients underwent IT, and after clinical restaging, 137 were operated upon with radical intent. Among these, 37 (19% of the overall and 27% of the surgical cohort) showed a pCR status and were included in this retrospective analysis. Survival rates and prognostic factors were analysed by the Kaplan-Meier, the log-rank and Cox regression analyses. RESULTS: The mean age and male/female ratio were 61.9 ± 9.8 years and 33/4, respectively. Before starting IT, the clinical staging was IIb in 2 (5%) patients, IIIa in 20 (54%) and IIIb in 15 (41%). Morbidity and 30-day mortality rates were 27 and 3%, respectively. The overall 3- and 5-year long-term survivals (LTSs) and disease-free survival (DFS) were 67 and 64% and 68 and 71%, respectively. Overall, 17 patients (46%) experienced a recurrence, occurring more frequently in a distant site (32%) than locally (19%). The analysis of the 5-year LTS suggests that (i) the initial single N2 station involvement (P = 0.010); (ii) the resection to a lesser extent than pneumonectomy (P = 0.005) and (iii) the adjuvant therapy (P = 0.005) are all positive prognostic factors. In particular, a 5-year hazard ratio of 8.21 (95% confidence interval 2.16-31.16, P = 0.002) was estimated by Cox regression analysis for subjects who did not undergo adjuvant therapy vs those who did. CONCLUSIONS: After induction radiochemotherapy followed by surgery in locally advanced NSCLC, a pCR is achieved in a remarkable proportion of cases (27% in our experience). In
- Published
- 2013
13. Successful multidisciplinary management of a primary mediastinal Ewing's sarcoma.
- Author
-
Margaritora, Stefano, Romano, Rosalia, Cesario, Alfredo, Lococo, Filippo, Petrone, Gianluigi, Granone, Pierluigi, Margaritora, Stefano (ORCID:0000-0002-9796-760X), Cesario, Alfredo (ORCID:0000-0003-4687-0709), Lococo, Filippo Maria (ORCID:0000-0002-9383-5554), Granone, Pierluigi (ORCID:0000-0002-8826-3045), Margaritora, Stefano, Romano, Rosalia, Cesario, Alfredo, Lococo, Filippo, Petrone, Gianluigi, Granone, Pierluigi, Margaritora, Stefano (ORCID:0000-0002-9796-760X), Cesario, Alfredo (ORCID:0000-0003-4687-0709), Lococo, Filippo Maria (ORCID:0000-0002-9383-5554), and Granone, Pierluigi (ORCID:0000-0002-8826-3045)
- Abstract
NO ABSTRACT AVAILABLE
- Published
- 2013
14. new sign of the slipping rib syndrome?
- Author
-
Romano, Rosalia, Gavezzoli, Diego, Gallazzi, Maria Sole, and Benvenuti, Mauro Roberto
- Published
- 2022
- Full Text
- View/download PDF
15. Long-term results in patients with pathological complete response after induction radiochemotherapy followed by surgery for locally advanced non-small-cell lung cancer†.
- Author
-
Lococo, Filippo, Cesario, Alfredo, Margaritora, Stefano, Dall'Armi, Valentina, Mattei, Francesca, Romano, Rosalia, Porziella, Venanzio, and Granone, Pierluigi
- Subjects
CANCER chemotherapy ,CANCER radiotherapy ,SMALL cell lung cancer ,LUNG surgery ,HEALTH outcome assessment ,MEDICAL statistics - Abstract
OBJECTIVES The outcome of locally advanced non-small-cell lung cancer (NSCLC) patients with pathological complete response (pCR)—pT0N0 —after induction chemoradiotherapy (IT) followed by surgery has, to date, only rarely been investigated. The long-term results in this highly selected subset of patients were evaluated and reported here to identify any predictive factors associated with prognosis. METHODS From January 1992 to December 2009, 195 consecutive locally advanced (T1–T4/N0–2/M0) NSCLC patients underwent IT, and after clinical restaging, 137 were operated upon with radical intent. Among these, 37 (19% of the overall and 27% of the surgical cohort) showed a pCR status and were included in this retrospective analysis. Survival rates and prognostic factors were analysed by the Kaplan–Meier, the log-rank and Cox regression analyses. RESULTS The mean age and male/female ratio were 61.9 ± 9.8 years and 33/4, respectively. Before starting IT, the clinical staging was IIb in 2 (5%) patients, IIIa in 20 (54%) and IIIb in 15 (41%). Morbidity and 30-day mortality rates were 27 and 3%, respectively. The overall 3- and 5-year long-term survivals (LTSs) and disease-free survival (DFS) were 67 and 64% and 68 and 71%, respectively. Overall, 17 patients (46%) experienced a recurrence, occurring more frequently in a distant site (32%) than locally (19%). The analysis of the 5-year LTS suggests that (i) the initial single N2 station involvement (P = 0.010); (ii) the resection to a lesser extent than pneumonectomy (P = 0.005) and (iii) the adjuvant therapy (P = 0.005) are all positive prognostic factors. In particular, a 5-year hazard ratio of 8.21 (95% confidence interval 2.16–31.16, P = 0.002) was estimated by Cox regression analysis for subjects who did not undergo adjuvant therapy vs those who did. CONCLUSIONS After induction radiochemotherapy followed by surgery in locally advanced NSCLC, a pCR is achieved in a remarkable proportion of cases (27% in our experience). In such patients, a rewarding LTS (64% at 5 years) could be expected, especially when a single N2 station is involved at diagnosis or when an adjuvant treatment is administered. Nevertheless, recurrences after surgery are quite common (46%) and this evidence deserves further investigations and deeper analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
16. Ten Years' Experience in Robotic-Assisted Thoracic Surgery for Early Stage Lung Cancer
- Author
-
Alessandro Borri, Lorenzo Spaggiari, Patrick Maisonneuve, Daniela Brambilla, Rosalia Romano, Monica Casiraghi, Cristina Diotti, Domenico Galetta, Adele Tessitore, Casiraghi, Monica, Galetta, Domenico, Borri, Alessandro, Tessitore, Adele, Romano, Rosalia, Diotti, Cristina, Brambilla, Daniela, Maisonneuve, Patrick, and Spaggiari, Lorenzo
- Subjects
Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Lung Neoplasms ,Time Factors ,medicine.medical_treatment ,Operative Time ,030204 cardiovascular system & hematology ,03 medical and health sciences ,Pneumonectomy ,Postoperative Complications ,0302 clinical medicine ,Robotic Surgical Procedures ,Risk Factors ,Carcinoma, Non-Small-Cell Lung ,robotic surgery ,Humans ,Medicine ,Lung cancer ,Lymph node ,Survival rate ,minimally invasive surgery ,non-small cell lung cancer ,Aged ,Neoplasm Staging ,Retrospective Studies ,business.industry ,Mortality rate ,Postoperative complication ,Length of Stay ,Middle Aged ,medicine.disease ,Surgery ,Treatment Outcome ,medicine.anatomical_structure ,030228 respiratory system ,Cardiothoracic surgery ,Lymphatic Metastasis ,Mediastinal lymph node ,Lymph Node Excision ,Female ,business ,Cardiology and Cardiovascular Medicine - Abstract
Background This study analyzed the short- and long-term outcomes of robotic-assisted thoracic surgery (RATS) for early stage non-small cell lung cancer (NSCLC). Methods From November 2006 to December 2016, we performed 363 RATS procedures. This study retrospectively reviewed 339 patients who underwent RATS for clinical stages I (n = 318) or II (n = 21) NSCLC. Results Twenty-nine patients underwent segmentectomy, 307 lobectomy, and 3 pneumonectomy. Conversion occurred in 22 patients (6.5%): 15 (4.4%) due to technical issues, 4 (1.2%) for oncological reasons, and 3 (0.9%) for bleeding. The median number of N1 and N2 stations resected was 2 and 3, respectively, and the median number of N1 and N2 lymph nodes resected was 9 and 6, respectively. Median operative time was 192 minutes for lobectomy, 172 minutes for segmentectomy, and 275 minutes for pneumonectomy. Median length of hospital stay was 5 days (2–191). The most common postoperative complication was prolonged air leak (12.1%). Major complications occurred in eight patients (2.4%). The 30-day and 90-day operative mortality was 0% and 0.3%, respectively. Two and 5-year cancer-specific survival rate was 96.1% and 91.5%, respectively. Five-year survival rate was 96.2% for patients who underwent segmentectomy, and 89.1% for lobectomy. All three patients who underwent pneumonectomy were alive at 5 years with no disease. Conclusions Besides the well-known short-term outcomes showing very low morbidity and mortality rates, mediastinal lymph node dissection during RATS adequately assesses lymph node stations detecting occult lymph node metastasis and leading to excellent oncologic results. However, these results await longer follow-up studies.
- Published
- 2019
17. Robotic-assisted thymectomy for early-stage thymoma: a propensity-score matched analysis
- Author
-
Daniela Brambilla, Lorenzo Spaggiari, Patrick Maisonneuve, Alessandro Borri, Domenico Galetta, Rosalia Romano, Adele Tessitore, Monica Casiraghi, Casiraghi, Monica, Galetta, Domenico, Borri, Alessandro, Tessitore, Adele, Romano, Rosalia, Brambilla, Daniela, Maisonneuve, Patrick, and Spaggiari, Lorenzo
- Subjects
Adult ,Male ,Robotic Surgical Procedure ,medicine.medical_specialty ,Thymoma ,Robotic assisted ,medicine.medical_treatment ,Operative Time ,Health Informatics ,030204 cardiovascular system & hematology ,Follow-Up Studie ,03 medical and health sciences ,0302 clinical medicine ,Postoperative Complications ,Robotic Surgical Procedures ,Retrospective Studie ,Medicine ,Stage iib ,Humans ,Robotic surgery ,Thoracotomy ,Thymus Neoplasm ,Stage (cooking) ,Propensity Score ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Thymus Neoplasms ,Length of Stay ,Middle Aged ,medicine.disease ,Thymectomy ,Surgery ,Tumor Burden ,Feasibility Studie ,030220 oncology & carcinogenesis ,Propensity score matching ,Feasibility Studies ,Female ,Postoperative Complication ,business ,Human ,Follow-Up Studies - Abstract
The aim of this study was to analyse the feasibility and safety of robotic-assisted thymectomy (RoT) in patients with clinically early stage thymoma, investigating clinical and early oncological results. Between 1998 and 2017, we retrospectively reviewed 76 (42.2%) patients who underwent radical thymectomy for clinically early stage thymoma (Masaoka-Koga I and II), identifying all patients who underwent RoT (n = 28) or open thymectomy (OT) with eligibility criteria for robotic surgery (n = 48). Using a propensity-score matched for tumor size (3.9 ± 1.8 cm) and stage (35% stage I, 42% stage IIA, 23% stage IIB), we paired 24 patients who had RoT with 24 patients undergoing OT. RoT was left-sided in 19 (79.2%) patients. None of the patients required conversion to open surgery. OT was via sternotomy in 21 (87.5%) patients and thoracotomy in 3 (12.5%). Mean operating time was shorter in the RoT group (117 ± 40 min) than in the OT (141 ± 46 min) (p = 0.06), even if not statistically significant. Length of stay was significantly shorter in the RoT group (mean 4.0 ± 1.9 days) than in the OT (mean 5.9 ± 1.7 days) (p = 0.0009). No significant difference between the two groups regarding post-operative complications. Five patients died in the OT group after a median follow-up of 6.1 years (only one for recurrence). After a median follow-up of 1.3 years, all patients in the RoT group were alive without disease. RoT is feasible and safe for early stage thymoma with clear advantage compared to OT in term of short term outcomes. A longer follow-up is needed to better evaluate the oncological results.
- Published
- 2018
18. Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?
- Author
-
Patrick Maisonneuve, Roberto Gasparri, Domenico Galetta, Monica Casiraghi, Lorenzo Spaggiari, Filippo de Marinis, Cesare Gridelli, Rosalia Romano, Daniela Brambilla, Alberto Sandri, Francesco Petrella, Juliana Guarize, Casiraghi, Monica, Guarize, Juliana, Sandri, Alberto, Maisonneuve, Patrick, Brambilla, Daniela, Romano, Rosalia, Galetta, Domenico, Petrella, Francesco, Gasparri, Roberto, Gridelli, Cesare, De Marinis, Filippo, and Spaggiari, Lorenzo
- Subjects
Male ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Bronchopleural fistula ,Induction therapy ,Gastroenterology ,03 medical and health sciences ,Pneumonectomy ,Postoperative Complications ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Humans ,Stage (cooking) ,Lung cancer ,Aged ,Neoplasm Staging ,Retrospective Studies ,Chemotherapy ,Advanced stage ,business.industry ,Incidence (epidemiology) ,Mortality rate ,Middle Aged ,Short and long term outcome ,medicine.disease ,Survival Analysis ,Occult ,Neoadjuvant Therapy ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Female ,Surgery ,Tomography, X-Ray Computed ,business ,Follow-Up Studies - Abstract
Background: Owing to the expected poor long-term outcomes and high postoperative morbidity and mortality, patients with stage IIIA-N2 tumors candidate to pneumonectomy (PN) are usually excluded from surgery. This study aims to analyze the outcome of patients who underwent PN to prove its safety and feasibility. Patients and Methods: We retrospectively analyzed data from 233 patients who underwent PN for N2 non–small-cell lung cancer (NSCLC) between 1998 and 2015. Eighty-five patients were occult N2 disease (group 1), whereas 148 patients underwent induction therapy (IT) for stage IIIA-N2 (group 2). Results: Overall morbidity, postoperative mortality, and 90-day mortality rates were 46.8%, 2.6%, and 8.6%, respectively. The 2 groups (group 1 vs. 2) had similar postoperative and 90-day mortality rates: 2.4% versus 2.7% (P = 1.00), and 9.4% versus 8.1% (P =.81), respectively. The incidence of major morbidity was higher and statistically significant in group 2 compared with group 1: 23% versus 12.9% (P =.1). Postoperative bronchopleural fistula occurred in 4.7% (4/85) of patients with occult N2 (group 1) and in 10.1% (15/148) of patients undergoing IT (group 2) (P = .10). Median overall survival (OS) was 2.2 years, with a 3 and 5-year OS of 43.4% and 31.6%, respectively. Disease-free survival (DFS) was 1.5 years, with 3 and 5-year DFS of 41.6% and 32%, respectively; no difference in OS and DFS between the 2 groups was found. Conclusions: Considering the acceptable morbidity and mortality rate and the long-term survival, PN should not be excluded for selected patients with stage IIIA-N2 NSCLC as a matter of principle. This study aims to analyze the outcome of patients with stage IIIA-N2 non–small-cell lung cancer who underwent pneumonectomy to prove its safety and feasibility, in particular after induction chemotherapy. Based on the acceptable morbidity and mortality rate and the long-term survival, pneumonectomy should not be excluded for selected patients as a matter of principle.
- Published
- 2019
- Full Text
- View/download PDF
19. A new sign of the slipping rib syndrome?
- Author
-
Romano R, Gavezzoli D, Gallazzi MS, and Benvenuti MR
- Subjects
- Chest Pain etiology, Humans, Thorax, Ultrasonography, Costal Cartilage surgery, Ribs diagnostic imaging, Ribs surgery
- Abstract
The slipping rib syndrome is characterized by burning pain in the lower thorax and upper abdomen, often disabling, caused by hypermobility of the costal cartilage with entrapment of the intercostal nerve. The syndrome is often underdiagnosed. The diagnosis is clinical and the definitive treatment is surgical, with an excellent result for pain relief. Based on the observation of 4 cases undergoing rib resection for SRS, we noticed a new possible sign of the disease. Our patients showed less thickness of the ipsilateral rectus abdominis muscle on ultrasound of the abdomen. The aim of this study is to demonstrate this sign in the diagnosis of SRS, to make this disease more recognizable and treatable., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.)
- Published
- 2022
- Full Text
- View/download PDF
20. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.
- Author
-
Milione M, Maisonneuve P, Grillo F, Mangogna A, Centonze G, Prinzi N, Pusceddu S, Garzone G, Cattaneo L, Busico A, Bossi P, Spaggiari P, Pellegrinelli A, Del Gobbo A, Ferrero S, Kankava K, Pruneri G, Rolli L, Roca E, Bercich L, Tironi A, Benvenuti MR, Gallazzi MS, Romano R, Berruti A, Pastorino U, and Capella C
- Subjects
- Carcinoma, Large Cell metabolism, Carcinoma, Large Cell mortality, Carcinoma, Neuroendocrine metabolism, Carcinoma, Neuroendocrine mortality, Humans, Lung Neoplasms metabolism, Lung Neoplasms mortality, Prognosis, Survival Analysis, Carcinoma, Large Cell diagnosis, Carcinoma, Neuroendocrine diagnosis, Ki-67 Antigen metabolism, Lung Neoplasms diagnosis
- Abstract
Background: Little information is available concerning prognostic factors for bronchopulmonary large cell neuroendocrine carcinomas (BP-LCNECs) and even less is known about combined LCNECs (Co-LCNECs). We investigated whether an integrated morphological, immunohistochemical, and molecular approach could be used for their prognostic evaluation., Methods: Morphological (including combined features), proliferative (mitotic count/Ki-67 index), immunohistochemical (napsin A, p40, TTF-1, CD44, OTP, SSTR2A, SSTR5, mASH1, p53, RB1, and MDM2), and genomic (TP53, RB1, ATM, JAK2, KRAS, and STK11) findings were analyzed in BP-LCNECs from 5 Italian centers, and correlated with overall survival (OS). The Ki-67 index was expressed as the percentage of positive cells in hot spots as indicated in the WHO 2019 Digestive System Tumors and, for Co-LCNECs, the Ki-67 index was evaluated only in the LCNEC component., Results: A total of 111 LCNECs were distinguished into 70 pure LCNECs, 35 Co-LCNECs (27 with adenocarcinoma [ADC] and 8 with squamous cell carcinoma [SqCC]), and 6 LCNECs with only napsin A immunoreactivity. The Ki-67 index cutoff at 55% evaluated in the neuroendocrine component was the most powerful predictor of OS (log-rank p = 0.0001) in all LCNECs; 34 cases had a Ki-67 index <55% (LCNEC-A) and 77 had a Ki-67 index ≥55% (LCNEC-B). Statistically significant differences in OS (log-rank p = 0.0001) were also observed between pure and Co-LCNECs. A significant difference in OS was found between pure LCNECs-A and Co-LCNECs-A (p < 0.05) but not between pure LCNECs-B and Co-LCNECs-B. Co-LCNEC-ADC and LCNEC napsin A+ cases had longer OS than pure LCNEC and Co-LCNEC-SqCC cases (log-rank p = 0.0001). On multivariable analysis, tumor location, pure versus combined features, and napsin A, but no single gene mutation, were significantly associated with OS after adjustment for Ki-67 index and study center (p < 0.05)., Conclusions: The Ki-67 proliferation index and the morphological characterization of combined features in LCNECs seem to be important tools for predicting clinical outcome in BP-LCNECs., (© 2020 S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.